Discover the Science of Health
An old disease is making a comeback, possibly due to a bacterial mutation. Seventeen states and Washington D.C. are reporting an increase in whooping cough this year. It’s an epidemic in Texas, on pace to be the worst in half a century [1]. The very young are most at risk.
By lowering the expression of a single gene, researchers at the National Institutes of Health have extended the average lifespan of a group of mice by about 20 percent — the equivalent of raising the average human lifespan by 16 years, from 79 to 95. This study appears in the August 29th edition of Cell Reports [1].
According to an international study led by researchers from the Virginia Commonwealth University (VCU) School of Pharmacy, multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity [1]. The discovery provides scientists with a better understanding the molecular and biological mechanisms involved with schizophrenia that may improve disease management and identify new drug targets. The study is published in the April issue of JAMA Psychiatry.
New research suggests that there is a strong link between depression and heart disease. Angelos Halaris, M.D., Ph.D., a psychiatrist at the Loyola University Medical Center, is so impressed by the strength of the correlation that he proposes a new medical subspecialty specifically to study and treat combined depression/heart disease patients. The new subspecialty, “Psychocardiology,” would be for the purpose of increasing physician and patient awareness of the strong link between the two disease processes, and would also increase the likelihood that patients with one of the two diseases — who would therefore be at risk of developing the other — would receive appropriate monitoring.
According to a new report released last month by the trade group Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical pipeline is innovative and robust, with a high percentage of potential first-in-class medicines (meaning a new treatment where nothing currently exists) targeting diseases with limited treatment options. In addition to identifying medicines in development for conditions and diseases such as septic shock, ovarian cancer, sickle cell disease, and Lou Gehrig’s disease (amyotrophic lateral sclerosis), which haven’t had any new product approvals in the last ten years, the report offers positive news for the rare disease community: one third of the products currently in clinical development have a rare disease designation by the U.S. Food and Drug Administration (FDA).
